Drugs / OMS643762
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02074410 | Jan → Oct 2014 | Huntington disease | Omeros Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01952132 | Sep 2013 → Apr 2014 | schizophrenia | Omeros Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMS643762 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01952132 ↗ |
| Route | Oral | “Orally administering OMS643762 low dose daily for 14 days” NCT01952132 ↗ |